生物技术公司AbCellera Biologics（股票代码：ABCL）在周五盘后交易中股价大涨5.37%，引发市场关注。
消息面上，斯迪富分析师Stephen Willey在最新的研究报告中维持了对AbCellera Biologics的买入评级，目标价保持在7美元不变。这一积极的分析师评级可能是推动公司股价上涨的主要因素。
值得注意的是，根据金融数据提供商TipRanks的统计，Stephen Willey分析师在过去一年的总体胜率为43.8%，平均回报率达6.8%。这一数据为投资者提供了额外的参考信息，可能进一步增强了市场对AbCellera Biologics前景的信心。然而，投资者在做出投资决策时仍需谨慎，全面考虑公司基本面和市场风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.